News and Announcements
Outsmarting chemo-resistant ovarian cancer
Synthetic ‘bladder patch’ promotes tissue regeneration, restores function
Hersam elected to National Academy of Engineering
SQI announces first round of Synthesizer Research Grants
Decorated nanoparticles prevent allergic reactions
Northwestern University researchers led by SQI member Evan Scott have developed the first selective therapy to prevent allergic reactions, which can range in severity from itchy hives and watery eyes to trouble breathing and even death.
To develop the new therapy, researchers decorated nanoparticles with antibodies capable of shutting down specific immune cells (called mast cells) responsible for allergic responses, as well as an allergen that corresponds to the patient’s specific allergy. In this two-step approach, the allergen engages the precise mast cells responsible for the specific allergy, and then the antibodies shut down only those cells.
Building teams for high-risk, high-reward research projects
Kelley elected to National Academy of Inventors
Ameer elected a Biomaterials Science and Engineering Fellow
Studies identify novel underpinnings of genetic ALS
A breath of fresh air keeps drug-producing cells alive longer
‘Super melanin’ heals skin injuries from sunburn, chemical burns
Meet the Researchers: Cara Smith
Developing new approaches for spinal cord injury
Northwestern researchers led by SQI director Samuel Stupp have developed a molecular “scaffold” capable of enhancing electrical activity and growth in neurons, which may prove useful in treating spinal cord injuries. The scaffolds were composed of a novel nanofiber that mimics the bioactivity of the protein netrin-1 and sustainably delivers signals to neurons over long periods of time.
SQI members Evangelos Kiskinis and Zaida Alvarez were coauthors of the paper, which was published in ACS Nano.
Identifying molecular culprits underlying organ rejection
A research team including SQI member Zheng Jenny Zhang has identified how the immune system can regulate organ rejection in mice, which may prove useful for improving transplant tolerance in humans.
The findings suggest that priming T-cells of transplant recipients with repeated injections of antigens from their organ donor may help the recipient’s body avoid organ rejection resulting from infection. The results of the study also identify donor MHC class II as a problematic antigen that may be a cause of rejection after severe infections.